Currently, governments around the world are withholding psilocybin treatment, treatment that could fundamentally change the lives of many who suffer with depression, argues Dana P. Saxon.
The drug remains illegal in many developed countries, despite the fact that study after study has shown that psilocybin has a stunning and positive on the psyches of patients suffering severe or chronic depression—even in small doses and/or after short-term dosing regimens.
Studies at NYU and Johns Hopkins focusing on depression and cancer, for example, ” found that a single dose of the medication can lead to an immediate reduction in depression and anxiety and that the lingering positive effect can last up to eight months,” Saxon notes.
“For physical and emotional pain alike, prescribed drugs are widely accepted as a primary solution for people who seek relief. You are diagnosed, placed in a box, and given the ‘right pills.'”
But what if those pills don’t work?
The problem, Saxon argues, is that there aren’t many opportunities for doctors and patients “to think outside the box” with regard to treatment, especially given the current state of health care in the U.S.